Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review

IF 6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Hongli Zhang, Jiewen Chen, Niansong Wang, Wei Chen, Youhua Xu, Dingkun Gui
{"title":"Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review","authors":"Hongli Zhang,&nbsp;Jiewen Chen,&nbsp;Niansong Wang,&nbsp;Wei Chen,&nbsp;Youhua Xu,&nbsp;Dingkun Gui","doi":"10.1002/dmrr.70077","DOIUrl":null,"url":null,"abstract":"<p>Diabetic kidney disease (DKD), affecting 20–40% of individuals with diabetes, is the leading cause of end-stage renal disease and represents a considerable global public health challenge owing to its high morbidity and mortality rates. Although traditional DKD management has focused on renin-angiotensin system blockade, the residual risk of renal failure persists despite optimised therapy. New therapeutic drugs, including glucagon-like peptide-1 receptor agonists, have triggered a paradigm shift in DKD treatment. Sodium-glucose cotransporter-2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and selective endothelin receptor antagonists have shown notable efficacy in improving renal outcomes in patients with type 2 diabetes mellitus. Furthermore, traditional Chinese medicine (TCM), with its holistic approach and evidence-based refinements, has shown considerable promise in DKD treatment, particularly as its theoretical framework continues to evolve. This study highlighted the transformative potential of multitargeted strategies in mitigating DKD progression, improving cardiovascular outcomes, and alleviating healthcare burdens. Future research should prioritise standardised trials, long-term safety assessments of TCM and personalised therapeutic regimens to optimise clinical management and patient quality of life.</p>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 6","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70077","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70077","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetic kidney disease (DKD), affecting 20–40% of individuals with diabetes, is the leading cause of end-stage renal disease and represents a considerable global public health challenge owing to its high morbidity and mortality rates. Although traditional DKD management has focused on renin-angiotensin system blockade, the residual risk of renal failure persists despite optimised therapy. New therapeutic drugs, including glucagon-like peptide-1 receptor agonists, have triggered a paradigm shift in DKD treatment. Sodium-glucose cotransporter-2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and selective endothelin receptor antagonists have shown notable efficacy in improving renal outcomes in patients with type 2 diabetes mellitus. Furthermore, traditional Chinese medicine (TCM), with its holistic approach and evidence-based refinements, has shown considerable promise in DKD treatment, particularly as its theoretical framework continues to evolve. This study highlighted the transformative potential of multitargeted strategies in mitigating DKD progression, improving cardiovascular outcomes, and alleviating healthcare burdens. Future research should prioritise standardised trials, long-term safety assessments of TCM and personalised therapeutic regimens to optimise clinical management and patient quality of life.

Abstract Image

糖尿病肾病药物治疗进展:系统综述
糖尿病肾病(DKD)影响到20-40%的糖尿病患者,是终末期肾病的主要原因,由于其高发病率和死亡率,是一个相当大的全球公共卫生挑战。尽管传统的DKD管理侧重于肾素-血管紧张素系统阻断,但尽管优化了治疗,肾衰竭的残余风险仍然存在。新的治疗药物,包括胰高血糖素样肽-1受体激动剂,已经引发了DKD治疗的范式转变。钠-葡萄糖共转运蛋白-2抑制剂、非甾体矿物皮质激素受体拮抗剂和选择性内皮素受体拮抗剂在改善2型糖尿病患者肾脏预后方面显示出显著的疗效。此外,传统中医(TCM)以其整体方法和基于证据的改进,在DKD治疗中显示出相当大的希望,特别是随着其理论框架的不断发展。该研究强调了多目标策略在缓解DKD进展、改善心血管结局和减轻医疗负担方面的变革潜力。未来的研究应优先考虑标准化试验、中医药的长期安全性评估和个性化治疗方案,以优化临床管理和患者生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes/Metabolism Research and Reviews
Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢
CiteScore
17.20
自引率
2.50%
发文量
84
审稿时长
4-8 weeks
期刊介绍: Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信